Investigating how modified RNA affects Alzheimer's disease
Official title: The role of N6-methyladenosine modified RNA in Alzheimer's disease
Funded at Boston University Medical Campus · NIH-10994140 · Data updated 2026-11-12
This study is looking at how a specific type of RNA modification might affect the buildup of tau protein in Alzheimer's disease, with the hope of finding new ways to help treat or slow down the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 15, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $717,209 |
| NIH project number | 5R01AG080810-03 |
| Project ID | NIH-10994140 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Alzheimer's disease or those at high risk due to genetic factors.
✕Less likely to help
Patients with non-neurodegenerative conditions or those without any risk factors for Alzheimer's disease may not benefit from this research.
What this research studies
This research explores the role of N6-methyladenosine (m6A) modified RNA in the development and progression of Alzheimer's disease. It focuses on how the accumulation of oligomeric tau protein interacts with m6A and its associated proteins, which may contribute to neurodegeneration. By analyzing these interactions, the research aims to uncover new mechanisms behind Alzheimer's pathology and identify potential therapeutic targets. The study utilizes advanced models to assess how manipulating m6A levels can influence tau pathology and disease progression.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that slow down or prevent the progression of Alzheimer's disease.
How similar studies have gone: Previous research has shown promising results in targeting RNA modifications for neurodegenerative diseases, indicating potential for success in this novel approach.
Where this research is happening
-
Boston University Medical Campus
Boston, United States Active
Researchers
- Principal investigator: Wolozin, Benjamin L — Boston University Medical Campus
- Study coordinator: Wolozin, Benjamin L
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.